Multimodality treatment for poorly differentiated neuroendocrine head and neck carcinomas - a single institution experience
Poorly differentiated head and neck neuroendocrine neoplasms are very rare. Surgical resection alone is insufficient to control the disease because of the high incidence of metastases. However, due to the lack of randomised clinical trials, treatment recommendations for this cancer vary considerably...
Gespeichert in:
Veröffentlicht in: | European journal of cancer care 2013-09, Vol.22 (5), p.648-652 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 652 |
---|---|
container_issue | 5 |
container_start_page | 648 |
container_title | European journal of cancer care |
container_volume | 22 |
creator | Görner, M. Brasch, F. Hirnle, P. Gehl, H.-B. Scholtz, L.-U. Wegehenkel, K. Sudhoff, H. |
description | Poorly differentiated head and neck neuroendocrine neoplasms are very rare. Surgical resection alone is insufficient to control the disease because of the high incidence of metastases. However, due to the lack of randomised clinical trials, treatment recommendations for this cancer vary considerably and are based on a limited number of small retrospective studies. We performed a retrospective analysis of all patients treated at our institution between 2003 and 2011. We assessed the stage of disease, type of therapy, toxicity, treatment response, time to progression and overall survival for all cases. Ten patients received combined modality treatment with chemotherapy in addition to surgery or radiation or both. According to Response Evaluation Criteria In Solid Tumours (RECIST) criteria, six of nine evaluable patients achieved complete remission and three patients had a partial remission. The mean duration of response was 358 days, with a range from 141 to 1080 days. The overall 1‐year survival rate was 88%; however, only approximately 50% of patients were alive after 2 years. Multimodality treatment concepts induce high initial remission rates in poorly differentiated neuroendocrine head and neck carcinomas. However, the time to relapse is usually short, and therefore long‐term prognosis of this rare head and neck tumour remains poor. |
doi_str_mv | 10.1111/ecc.12070 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_1529704207</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3317784501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3920-be7b55af54060ebaa9db7dbfc21f6784a0c59763f6a0e7367fdcf2bec86886443</originalsourceid><addsrcrecordid>eNo9UU1P3DAQtSpQ2dIe-APIEueAP2I7OVYRpZV2l0urHi3HHreGxN46jmDFn29ggbnM6M17M9J7CJ1RckmXugJrLykjinxAK8qlqBgX9RFakVbSStSMn6BP03RHCOW0rT-iE8YVoawhK_S0mYcSxuTMEMoelwymjBAL9injXUp52GMXvIe8gMEUcDjCnBNEl2wOEfBfMA6b-Izbe2xNtiGm0Uy4wgZPIf4ZAIc4lVDmElLE8LiDHCBa-IyOvRkm-PLaT9Gvb9c_u-_V-vbmR_d1XVneMlL1oHohjBc1kQR6Y1rXK9d7y6iXqqkNsaJVkntpCCgulXfWsx5sI5tG1jU_RReHu7uc_s0wFX2X5hyXl5oK1ipSL94trPNX1tyP4PQuh9HkvX7zaiFcHQgPYYD9-54S_RyCXkLQLyHo6657GRZFdVCEqcDju8Lkey0VV0L_3t7oDd1suzXZ6o7_BxCjitE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1529704207</pqid></control><display><type>article</type><title>Multimodality treatment for poorly differentiated neuroendocrine head and neck carcinomas - a single institution experience</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Görner, M. ; Brasch, F. ; Hirnle, P. ; Gehl, H.-B. ; Scholtz, L.-U. ; Wegehenkel, K. ; Sudhoff, H.</creator><creatorcontrib>Görner, M. ; Brasch, F. ; Hirnle, P. ; Gehl, H.-B. ; Scholtz, L.-U. ; Wegehenkel, K. ; Sudhoff, H.</creatorcontrib><description>Poorly differentiated head and neck neuroendocrine neoplasms are very rare. Surgical resection alone is insufficient to control the disease because of the high incidence of metastases. However, due to the lack of randomised clinical trials, treatment recommendations for this cancer vary considerably and are based on a limited number of small retrospective studies. We performed a retrospective analysis of all patients treated at our institution between 2003 and 2011. We assessed the stage of disease, type of therapy, toxicity, treatment response, time to progression and overall survival for all cases. Ten patients received combined modality treatment with chemotherapy in addition to surgery or radiation or both. According to Response Evaluation Criteria In Solid Tumours (RECIST) criteria, six of nine evaluable patients achieved complete remission and three patients had a partial remission. The mean duration of response was 358 days, with a range from 141 to 1080 days. The overall 1‐year survival rate was 88%; however, only approximately 50% of patients were alive after 2 years. Multimodality treatment concepts induce high initial remission rates in poorly differentiated neuroendocrine head and neck carcinomas. However, the time to relapse is usually short, and therefore long‐term prognosis of this rare head and neck tumour remains poor.</description><identifier>ISSN: 0961-5423</identifier><identifier>EISSN: 1365-2354</identifier><identifier>DOI: 10.1111/ecc.12070</identifier><identifier>PMID: 23701280</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carboplatin - administration & dosage ; Carcinoma, Neuroendocrine - drug therapy ; Carcinoma, Neuroendocrine - radiotherapy ; Carcinoma, Neuroendocrine - surgery ; Carcinoma, Small Cell - drug therapy ; Carcinoma, Small Cell - radiotherapy ; Carcinoma, Small Cell - surgery ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - radiotherapy ; Carcinoma, Squamous Cell - surgery ; Cisplatin - administration & dosage ; Combined Modality Therapy - methods ; etoposide ; Etoposide - administration & dosage ; Female ; head and neck cancer ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - radiotherapy ; Head and Neck Neoplasms - surgery ; Humans ; Male ; Medical prognosis ; Medical research ; Middle Aged ; neuroendocrine ; Ovarian cancer ; platin ; poorly differentiated neuroendocrine cancer ; Retrospective Studies ; small cell neuroendocrine cancer ; Squamous Cell Carcinoma of Head and Neck ; Treatment Outcome</subject><ispartof>European journal of cancer care, 2013-09, Vol.22 (5), p.648-652</ispartof><rights>2013 John Wiley & Sons Ltd</rights><rights>2013 John Wiley & Sons Ltd.</rights><rights>Copyright © 2013 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3920-be7b55af54060ebaa9db7dbfc21f6784a0c59763f6a0e7367fdcf2bec86886443</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fecc.12070$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fecc.12070$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23701280$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Görner, M.</creatorcontrib><creatorcontrib>Brasch, F.</creatorcontrib><creatorcontrib>Hirnle, P.</creatorcontrib><creatorcontrib>Gehl, H.-B.</creatorcontrib><creatorcontrib>Scholtz, L.-U.</creatorcontrib><creatorcontrib>Wegehenkel, K.</creatorcontrib><creatorcontrib>Sudhoff, H.</creatorcontrib><title>Multimodality treatment for poorly differentiated neuroendocrine head and neck carcinomas - a single institution experience</title><title>European journal of cancer care</title><addtitle>Eur J Cancer Care (Engl)</addtitle><description>Poorly differentiated head and neck neuroendocrine neoplasms are very rare. Surgical resection alone is insufficient to control the disease because of the high incidence of metastases. However, due to the lack of randomised clinical trials, treatment recommendations for this cancer vary considerably and are based on a limited number of small retrospective studies. We performed a retrospective analysis of all patients treated at our institution between 2003 and 2011. We assessed the stage of disease, type of therapy, toxicity, treatment response, time to progression and overall survival for all cases. Ten patients received combined modality treatment with chemotherapy in addition to surgery or radiation or both. According to Response Evaluation Criteria In Solid Tumours (RECIST) criteria, six of nine evaluable patients achieved complete remission and three patients had a partial remission. The mean duration of response was 358 days, with a range from 141 to 1080 days. The overall 1‐year survival rate was 88%; however, only approximately 50% of patients were alive after 2 years. Multimodality treatment concepts induce high initial remission rates in poorly differentiated neuroendocrine head and neck carcinomas. However, the time to relapse is usually short, and therefore long‐term prognosis of this rare head and neck tumour remains poor.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Neuroendocrine - drug therapy</subject><subject>Carcinoma, Neuroendocrine - radiotherapy</subject><subject>Carcinoma, Neuroendocrine - surgery</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>Carcinoma, Small Cell - radiotherapy</subject><subject>Carcinoma, Small Cell - surgery</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Carcinoma, Squamous Cell - surgery</subject><subject>Cisplatin - administration & dosage</subject><subject>Combined Modality Therapy - methods</subject><subject>etoposide</subject><subject>Etoposide - administration & dosage</subject><subject>Female</subject><subject>head and neck cancer</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Head and Neck Neoplasms - surgery</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>neuroendocrine</subject><subject>Ovarian cancer</subject><subject>platin</subject><subject>poorly differentiated neuroendocrine cancer</subject><subject>Retrospective Studies</subject><subject>small cell neuroendocrine cancer</subject><subject>Squamous Cell Carcinoma of Head and Neck</subject><subject>Treatment Outcome</subject><issn>0961-5423</issn><issn>1365-2354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UU1P3DAQtSpQ2dIe-APIEueAP2I7OVYRpZV2l0urHi3HHreGxN46jmDFn29ggbnM6M17M9J7CJ1RckmXugJrLykjinxAK8qlqBgX9RFakVbSStSMn6BP03RHCOW0rT-iE8YVoawhK_S0mYcSxuTMEMoelwymjBAL9injXUp52GMXvIe8gMEUcDjCnBNEl2wOEfBfMA6b-Izbe2xNtiGm0Uy4wgZPIf4ZAIc4lVDmElLE8LiDHCBa-IyOvRkm-PLaT9Gvb9c_u-_V-vbmR_d1XVneMlL1oHohjBc1kQR6Y1rXK9d7y6iXqqkNsaJVkntpCCgulXfWsx5sI5tG1jU_RReHu7uc_s0wFX2X5hyXl5oK1ipSL94trPNX1tyP4PQuh9HkvX7zaiFcHQgPYYD9-54S_RyCXkLQLyHo6657GRZFdVCEqcDju8Lkey0VV0L_3t7oDd1suzXZ6o7_BxCjitE</recordid><startdate>201309</startdate><enddate>201309</enddate><creator>Görner, M.</creator><creator>Brasch, F.</creator><creator>Hirnle, P.</creator><creator>Gehl, H.-B.</creator><creator>Scholtz, L.-U.</creator><creator>Wegehenkel, K.</creator><creator>Sudhoff, H.</creator><general>Blackwell Publishing Ltd</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>8FD</scope><scope>ASE</scope><scope>FPQ</scope><scope>FR3</scope><scope>K6X</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>201309</creationdate><title>Multimodality treatment for poorly differentiated neuroendocrine head and neck carcinomas - a single institution experience</title><author>Görner, M. ; Brasch, F. ; Hirnle, P. ; Gehl, H.-B. ; Scholtz, L.-U. ; Wegehenkel, K. ; Sudhoff, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3920-be7b55af54060ebaa9db7dbfc21f6784a0c59763f6a0e7367fdcf2bec86886443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Neuroendocrine - drug therapy</topic><topic>Carcinoma, Neuroendocrine - radiotherapy</topic><topic>Carcinoma, Neuroendocrine - surgery</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>Carcinoma, Small Cell - radiotherapy</topic><topic>Carcinoma, Small Cell - surgery</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Carcinoma, Squamous Cell - surgery</topic><topic>Cisplatin - administration & dosage</topic><topic>Combined Modality Therapy - methods</topic><topic>etoposide</topic><topic>Etoposide - administration & dosage</topic><topic>Female</topic><topic>head and neck cancer</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Head and Neck Neoplasms - surgery</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>neuroendocrine</topic><topic>Ovarian cancer</topic><topic>platin</topic><topic>poorly differentiated neuroendocrine cancer</topic><topic>Retrospective Studies</topic><topic>small cell neuroendocrine cancer</topic><topic>Squamous Cell Carcinoma of Head and Neck</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Görner, M.</creatorcontrib><creatorcontrib>Brasch, F.</creatorcontrib><creatorcontrib>Hirnle, P.</creatorcontrib><creatorcontrib>Gehl, H.-B.</creatorcontrib><creatorcontrib>Scholtz, L.-U.</creatorcontrib><creatorcontrib>Wegehenkel, K.</creatorcontrib><creatorcontrib>Sudhoff, H.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Technology Research Database</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Engineering Research Database</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>European journal of cancer care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Görner, M.</au><au>Brasch, F.</au><au>Hirnle, P.</au><au>Gehl, H.-B.</au><au>Scholtz, L.-U.</au><au>Wegehenkel, K.</au><au>Sudhoff, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multimodality treatment for poorly differentiated neuroendocrine head and neck carcinomas - a single institution experience</atitle><jtitle>European journal of cancer care</jtitle><addtitle>Eur J Cancer Care (Engl)</addtitle><date>2013-09</date><risdate>2013</risdate><volume>22</volume><issue>5</issue><spage>648</spage><epage>652</epage><pages>648-652</pages><issn>0961-5423</issn><eissn>1365-2354</eissn><abstract>Poorly differentiated head and neck neuroendocrine neoplasms are very rare. Surgical resection alone is insufficient to control the disease because of the high incidence of metastases. However, due to the lack of randomised clinical trials, treatment recommendations for this cancer vary considerably and are based on a limited number of small retrospective studies. We performed a retrospective analysis of all patients treated at our institution between 2003 and 2011. We assessed the stage of disease, type of therapy, toxicity, treatment response, time to progression and overall survival for all cases. Ten patients received combined modality treatment with chemotherapy in addition to surgery or radiation or both. According to Response Evaluation Criteria In Solid Tumours (RECIST) criteria, six of nine evaluable patients achieved complete remission and three patients had a partial remission. The mean duration of response was 358 days, with a range from 141 to 1080 days. The overall 1‐year survival rate was 88%; however, only approximately 50% of patients were alive after 2 years. Multimodality treatment concepts induce high initial remission rates in poorly differentiated neuroendocrine head and neck carcinomas. However, the time to relapse is usually short, and therefore long‐term prognosis of this rare head and neck tumour remains poor.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>23701280</pmid><doi>10.1111/ecc.12070</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0961-5423 |
ispartof | European journal of cancer care, 2013-09, Vol.22 (5), p.648-652 |
issn | 0961-5423 1365-2354 |
language | eng |
recordid | cdi_proquest_journals_1529704207 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Neuroendocrine - drug therapy Carcinoma, Neuroendocrine - radiotherapy Carcinoma, Neuroendocrine - surgery Carcinoma, Small Cell - drug therapy Carcinoma, Small Cell - radiotherapy Carcinoma, Small Cell - surgery Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - radiotherapy Carcinoma, Squamous Cell - surgery Cisplatin - administration & dosage Combined Modality Therapy - methods etoposide Etoposide - administration & dosage Female head and neck cancer Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - radiotherapy Head and Neck Neoplasms - surgery Humans Male Medical prognosis Medical research Middle Aged neuroendocrine Ovarian cancer platin poorly differentiated neuroendocrine cancer Retrospective Studies small cell neuroendocrine cancer Squamous Cell Carcinoma of Head and Neck Treatment Outcome |
title | Multimodality treatment for poorly differentiated neuroendocrine head and neck carcinomas - a single institution experience |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T10%3A19%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multimodality%20treatment%20for%20poorly%20differentiated%20neuroendocrine%20head%20and%20neck%20carcinomas%20-%20a%20single%20institution%20experience&rft.jtitle=European%20journal%20of%20cancer%20care&rft.au=G%C3%B6rner,%20M.&rft.date=2013-09&rft.volume=22&rft.issue=5&rft.spage=648&rft.epage=652&rft.pages=648-652&rft.issn=0961-5423&rft.eissn=1365-2354&rft_id=info:doi/10.1111/ecc.12070&rft_dat=%3Cproquest_pubme%3E3317784501%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1529704207&rft_id=info:pmid/23701280&rfr_iscdi=true |